Fischer Medical Ventures Limited has completed the conversion of 60 lakh convertible warrants into equity shares, as announced through a Board resolution dated March 31, 2026. The conversion represents a significant capital infusion for the company, with total consideration received amounting to Rs. 10.53 crores.

Warrant Conversion Details

The Board of Directors approved the allotment through a Circular Resolution, converting 60,00,000 convertible warrants into an equal number of equity shares. The conversion was executed at an issue price of Rs. 23.40 per share, which includes a premium of Rs. 22.40 over the face value of Re. 1 per share.

Allottee Information

The entire warrant conversion was executed by a single promoter entity. Mr. Shankar Varadharajan, classified under the promoter category, exercised his option to convert all 60 lakh warrants held by him.

Financial Structure

The warrant conversion involved payment of the remaining exercise price of Rs. 17.55 per warrant, representing 75% of the total warrant exercise price of Rs. 23.40. This indicates that 25% of the exercise price was likely paid at the time of initial warrant issuance, with the remaining amount paid upon conversion.

Regulatory Compliance

Fischer Medical Ventures disclosed this development in compliance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited and National Stock Exchange of India Limited about this material development through proper regulatory channels.

The conversion strengthens the company's equity base while providing the promoter with increased shareholding in the company. The allotment was made for cash consideration, enhancing the company's financial position through the substantial capital infusion of over Rs. 10 crores.

Fischer medical ventures Limited has announced a key management appointment following its Board of Directors meeting held on March 24, 2026. The company has appointed Mr. Balaji Gandla as Company Secretary and Compliance Officer, marking an important addition to its leadership team.

Board Meeting Outcomes

The Board of Directors approved the appointment during their meeting on March 24, 2026, which was conducted from 11:10 AM (IST) to 12:20 PM (IST). The appointment was made pursuant to Section 203 of the Companies Act, 2013 and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Professional Background

Mr. Balaji Gandla brings substantial expertise to his new role. He is a qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI). His educational background includes a Bachelor of Commerce degree from the University of Madras, Chennai.

Key Qualifications and Experience

• Over a decade of professional experience in corporate governance
• Specialization in Secretarial Compliance and Regulatory Affairs
• Proven track record in managing end-to-end secretarial and compliance functions
• Experience with both listed and unlisted companies
• Expertise in liaison and correspondence with regulatory authorities including ROC, SEBI, BSE, and NSE

Dual Responsibilities

In addition to his role at Fischer Medical Ventures Limited, Mr. Gandla will simultaneously serve as Company Secretary of the company's wholly owned subsidiary, Time Medical International Ventures (India) Private Limited, effective from the same date.

Regulatory Compliance

The appointment fulfills the company's obligations under various regulatory frameworks and demonstrates Fischer Medical Ventures Limited's commitment to maintaining robust corporate governance standards. The company has duly informed both BSE Limited and the National Stock Exchange of India Limited about this key management personnel change as required under SEBI regulations.